Drug Trial Radar · NCT01194934
NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 2010
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the second clinical study of NOX-A12. This study intends to provide information on the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeated intravenous doses of NOX-A12 (2.0 and 4.0 mg/kg/d) alone and to compare the mobilization of hematopoietic stem cells (HSC) obtained with NOX-A12 alone with that obtained in combination with filgrastim in healthy subjects. A single center, open-label, repeated dose study design is selected to best address the study objectives.The results from this study will establish the basis for further development of NOX-A12 in lymphoma patients undergoing autologous hematopoietic stem cell transplantation
Conditions
- Hematopoietic Stem Cell Transplantation
Interventions
NOX-A12Drug
4 mg/kg daily IV for 5 days
NOX-A12Drug
2 mg/kg daily IV for 5 days
FilgrastimDrug
5 µg/kg SC daily for 5 days
NOX-A12 in combination with FilgrastimDrug
Safe and efficacious dose regimen according to results of groups A and B
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety and tolerability of repeated doses of NOX-A12 alone and in combination with filgrastim in healthy subjects.Time frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charité Research Organisation GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.